RET and non-small cell lung carcinoma: TP53 mutation has been identified as the most prevalent concomitant mutation in RET-rearranged NSCLC and is associated with a poor prognosis.27 Our analysis of SY-5007’s efficacy in patients with detectable RET variations at baseline, stratified by TP53 mutation status, revealed that among those with a concomitant TP53 mutation, SY-5007 demonstrated an ORR of 50.0% (11/22, 95% CI 28.2–71.8%) and a median PFS of 10.1 months (95% CI 6.21-NE).